This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Epizyme 将来の成長
Future 基準チェック /26
主要情報
15.8%
収益成長率
16.6%
EPS成長率
Biotechs 収益成長 | 28.4% |
収益成長率 | 37.6% |
将来の株主資本利益率 | n/a |
アナリストカバレッジ | Low |
最終更新日 | n/a |
今後の成長に関する最新情報
Recent updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16Epizyme: Taking Advantage Of Recent Sell-Off
Nov 25Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?
Sep 14Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts
Aug 10Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
Jun 22Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jun 08Epizyme gains as peer Constellation attracts sizable premium from MorphoSys
Jun 02Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%
Feb 25Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jan 16Epizyme says Boehringer terminates collaboration agreement
Dec 24Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?
Dec 12Epizyme Q3 2020 Earnings Preview
Nov 05業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2024 | 136 | -173 | N/A | N/A | 3 |
12/31/2023 | 80 | -196 | N/A | N/A | 4 |
12/31/2022 | 49 | -182 | N/A | N/A | 4 |
6/30/2022 | 53 | -208 | -209 | -209 | N/A |
3/31/2022 | 38 | -236 | -211 | -210 | N/A |
12/31/2021 | 37 | -251 | -227 | -227 | N/A |
9/30/2021 | 34 | -267 | -229 | -228 | N/A |
6/30/2021 | 33 | -257 | -229 | -228 | N/A |
3/31/2021 | 22 | -251 | -250 | -224 | N/A |
12/31/2020 | 16 | -232 | -257 | -206 | N/A |
9/30/2020 | 12 | -222 | -239 | -189 | N/A |
6/30/2020 | 14 | -202 | -235 | -184 | N/A |
3/31/2020 | 17 | -192 | -200 | -174 | N/A |
12/31/2019 | 24 | -173 | -148 | -147 | N/A |
9/30/2019 | 29 | -140 | -135 | -134 | N/A |
6/30/2019 | 23 | -141 | -132 | -132 | N/A |
3/31/2019 | 30 | -122 | -123 | -123 | N/A |
12/31/2018 | 22 | -124 | -122 | -122 | N/A |
9/30/2018 | 12 | -137 | -130 | -129 | N/A |
6/30/2018 | 12 | -137 | -133 | -133 | N/A |
3/31/2018 | 10 | -136 | -119 | -118 | N/A |
12/31/2017 | 10 | -134 | -121 | -120 | N/A |
9/30/2017 | 10 | -133 | -112 | -111 | N/A |
6/30/2017 | 17 | -120 | -98 | -97 | N/A |
3/31/2017 | 8 | -120 | -105 | -104 | N/A |
12/31/2016 | 8 | -110 | -97 | -96 | N/A |
9/30/2016 | 8 | -97 | -97 | -97 | N/A |
6/30/2016 | 2 | -96 | -80 | -79 | N/A |
3/31/2016 | 2 | -94 | N/A | -76 | N/A |
12/31/2015 | 3 | -132 | N/A | -73 | N/A |
9/30/2015 | 12 | -125 | N/A | -72 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: EPZM is forecast to remain unprofitable over the next 3 years.
収益対市場: EPZM is forecast to remain unprofitable over the next 3 years.
高成長収益: EPZM is forecast to remain unprofitable over the next 3 years.
収益対市場: EPZM's revenue (37.6% per year) is forecast to grow faster than the US market (7.9% per year).
高い収益成長: EPZM's revenue (37.6% per year) is forecast to grow faster than 20% per year.
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: Insufficient data to determine if EPZM's Return on Equity is forecast to be high in 3 years time